Who May Benefit?

Words "Some migraine treatments fail when patients depend on them the most" on black background
Words "Some migraine treatments fail when patients depend on them the most" on black background

Patient dissatisfaction is underreported—96% of survey patients said they were dissatisfied with at least one aspect of their migraine treatment¹*

Adding Trudhesa® to your treatment toolbox could benefit patients like these:

All patient images are actor portrayals.

*In a survey of 3930 US adults with migraine who reported use of oral acute prescription medication.1

Morning migraine with nausea

Patient history

  • Has about 4 to 5 migraine days per month accompanied with nausea; worst migraine attacks either come on rapidly or start before he wakes up
  • Attacks come on quickly; oral triptan can’t provide pain relief
  • Misses 1 to 2 days of work every month


Needs a reliable treatment that can provide pain freedom, even when taken late into an attack

Migraine attacks that break through while on prevention

Patient history

  • Diagnosed with migraine in high school
  • Has significant photosensitivity, but can’t wear sunglasses due to allodynia
  • Cannot tolerate triptans, and has been on a preventive anti-CGRP for a year, which has reduced her headache frequency by about half
  • Has tried gepants to treat her remaining attacks; however, they do not provide adequate pain freedom


Needs a reliable and tolerable treatment that works differently from current medication and delivers pain freedom even when taken late into an attack

Long-lasting migraine, headache recurrence

Patient history

  • Experiences attacks that last a couple days, especially when attacks are associated with menstruation
  • Has been on an anti-CGRP and treats attacks with a gepant but struggles with getting sustained relief, often having to take multiple doses
  • Worries her attacks will keep her away from work for too long or result in missing family events


Needs a medication that can provide rapid and sustained relief with one dose, even if taken late

Dissatisfied with migraine treatment, has controlled hypertension

Patient history

  • Has a long history of migraine with aura; attacks cause her to cancel plans for the day
  • Has no other medical problems aside from hypertension that is under control with hydrochlorothiazide
  • Cannot get consistent relief with her triptan or gepant, so she’s inquiring about a more effective acute treatment


Needs a reliable and tolerable treatment that can act fast and provide pain freedom, even if taken late

Be Direct.

It may help them get the relief they need.

Consider asking your patients these questions to see if they may be right for Trudhesa:

  • “Does a single dose of your current medication give you the migraine symptom relief you need for at least 24 hours?”7
  • “Do you feel like you can rely on your current acute medication to work when you need it to?”5,7-9
  • “Do you ever have any stomach issues or nausea when you’re having a migraine attack?”10,11
  • “Are you always able to take your migraine pill or dissolving tablet early enough for it to work?”3,12
Product image of Trudhesa® featuring the medication vial and the POD device vertical upright facing right and tilted down


Actor portrayal of Trudhesa patient smiling with ponytail and looking to the bottom left

References: 1. Lipton RB, Munjal S, Buse DC, et al. Unmet acute treatment needs from the 2017 Migraine in America Symptoms and Treatment Study. Headache. 2019;59(8):1310-1323. 2. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 2021;61(8):1214-1226. 3. Data on File. Impel Pharmaceuticals. 2020. 4. Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. STOP 101: a phase 1, randomized, open-label, comparative bioavailability study of INP104, dihydroergotamine mesylate (DHE) administered intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in healthy adult subjects. Headache. 2019;59(3):394-409. 5. Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) – then and now: a narrative review. Headache. 2020;60(1):40-57. 6. Craig K, Jeleva M, Hocevar-Trnka J. Cardiovascular safety results of INP104 (POD-DHE) from the STOP 301 phase 3 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 7. Tepper SJ, Ailani J, Shrewsbury SB, Aurora SK. Recurrence rates for INP104 for the acute treatment of migraine: results from the phase 3 STOP 301 study. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 8. Wells RE, Markowitz SY, Baron EP, et al. Identifying the factors underlying discontinuation of triptans. Headache. 2014;54(2):278-289. 9. Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004;44(7):661-668. 10. Aurora SK, Papapetropoulos, Kori S. Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implication. Cephalalgia. 2013;33(6):408-415. 11. Trudhesa. Prescribing information. Impel Pharmaceuticals; 2021. 12. Aurora SK, Ray S, Satterly K, Shrewsbury SB, Hoekman J. Does dihydroergotamine treat the “whole migraine”? Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 2020.